Prof Elke de Jong focussed her presentation on data from randomised clinical trials (RCT)
and realworld evidence (RWE) from psoriasis patient registries. Such data is complementary …

Abstract Purpose of Review The purpose of this article is to review current understanding of
the role of IL-23 in psoriasis and the available results to date on clinical trials establishing …

Background Psoriasis is a chronic immune-mediated inflammatory skin disease for which
biologics are effective treatments. Dose reduction (DR) of the first generation biologics …

The approved biologics targeting interleukin (IL)-23 p19 for the treatment of moderate-to-
severe plaque psoriasis, including guselkumab, tildrakizumab, and risankizumab, have …

Purpose This review article aims to compare global dermatologic organizations and the
clinical practice guidelines available for the use of interleukin (IL)-23 inhibitors in the …

Several systemic therapies are currently available for the treatment of patients with moderate-
to-severe psoriasis. Biologics changed the game for treatment. Continued study of and …

4 Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda Usl-IRCCS di Reggio Emilia,
Reggio Emilia, Italy 5 Dermatology Unit, Infermi Hospital, Rimini, AUSL Romagna, Italy 6 …

Blocking of IL-23 has shown a profound effect on patient outcomes in psoriasis. The current
IL-23 binding monoclonal antibodies show differences in dosing regimens …

Interleukin (IL)-17 and IL-23 inhibitors are both approved for the treatment of moderate-to-
severe plaque psoriasis (PsO), as well as psoriatic arthritis (PsA). In the absence of head-to …

Psoriasis is a chronic inflammatory skin disease affecting up to 3% of the population
worldwide [1]. Plaque psoriasis is the most common clinical subtype, and it presents with …